The DOI matches its Crossref record.
Low molecular weight, non-peptide fibrinogen receptor antagonists
Abstract
The tetrapeptide H-Arg-Gly-Asp-Ser-OH (1) (RGDS), representing a recognition sequence of fibrinogen for its platelet receptor GP IIb-IIIa (integrin alpha IIb beta 3), served as lead compound for the development of highly potent and selective fibrinogen receptor antagonists. Replacement of the N-terminal arginine by p-amidinophenylalanine or the Gly moiety by m-aminobenzoic acid led to compounds which are superior to the lead peptide with regard to activity and selectivity for GP IIb-IIIa vs the closely related vitronectin receptor alpha v beta 3. By random screening [(p-amidinobenzenesulfonamido)ethyl]-p-phenoxyacetic acid derivatives have been identified as fibrinogen receptor antagonists. Further structure-activity relationship studies culminated in the preparation of N-[N-[N-(p-amidinobenzoyl)-beta-alanyl]-L-alpha-aspartyl]-3-phenyl-L- alanine (29h, Ro 43-5054) and [[1-[N-(p-amidinobenzoyl)-L-tyrosyl]-4-piperidinyl]oxy]acetic acid (37f, Ro 44-9883), which exhibit very high activity as platelet aggregation inhibitors (IC50s 0.06 and 0.03 microM, respectively, human PRP/ADP) as well as marked selectivity for GP IIb-IIIa vs alpha v beta 3. Since the activity of 37f in dogs declines according to a two-compartment model with an initial phase having a t1/2 of 8 min and a second phase with a t1/2 of 110 min, this compound is a suitable candidate for the development as iv platelet inhibitor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Integrins: Emerging Paradigms of Signal Transduction
Schwartz, M. A., Schaller, M. D., & Ginsberg, M. H. (1995) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cb.11.110195.003001 · Cited by 1,594
Blood-borne tissue factor: Another view of thrombosis
Giesen, P. L. A., Rauch, U., Bohrmann, B., Kling, D., Roqué, M., Fallon, J. T., Badimon, J. J., Himber, J., Riederer, M. A., & Nemerson, Y. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2311 · Cited by 991
Patrono, C., Coller, B., Dalen, J. E., Fitz Gerald, G. A., Fuster, V., Gent, M., Hirsh, J., & Roth, G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.39s · Cited by 963
Peptidomimetics—Tailored Enzyme Inhibitors
Gante, J. (1994) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199416991 · Cited by 825
Hughes, P. E., Diaz-Gonzalez, F., Leong, L., Wu, C., McDonald, J. A., Shattil, S. J., & Ginsberg, M. H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.12.6571 · Cited by 565
Suppression of Integrin Activation: A Novel Function of a Ras/Raf-Initiated MAP Kinase Pathway
Hughes, P. E., Renshaw, M. W., Pfaff, M., Forsyth, J., Keivens, V. M., Schwartz, M. A., & Ginsberg, M. H. (1997) · Cell · doi:10.1016/s0092-8674(00)81892-9 · Cited by 489
Small Bioactive Peptides for Biomaterials Design and Therapeutics
Hamley, I. W. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00522 · Cited by 461
Modulation of cell migration by integrin-mediated cytoskeletal linkages and ligand-binding affinity.
Huttenlocher, A., Ginsberg, M. H., & Horwitz, A. F. (1996) · The Journal of cell biology · doi:10.1083/jcb.134.6.1551 · Cited by 364
Wu, C., Keivenst, V. M., O'Toole, T. E., McDonald, J. A., & Ginsberg, M. H. (1995) · Cell · doi:10.1016/0092-8674(95)90184-1 · Cited by 347
Adhesion Molecules in Inflammatory Diseases
Gonz??lez-Amaro, R., D??az-Gonz??lez, F., & S??nchez-Madrid, F. (1998) · Drugs · doi:10.2165/00003495-199856060-00003 · Cited by 98
Metadata
- Authors
- Alig, L., Edenhofer, A., Hadvary, P., Huerzeler, M., Knopp, D., Mueller, M., Steiner, B., Trzeciak, A., & Weller, T.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1992-11
- Volume
- 35
- Issue
- 23
- Pages
- 4393-4407
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1997377540
- Cited by
- 190
- References
- 0
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.